Effect of -202 A/C IGFBP-3 polymorphisms on growth responses in children with idiopathic short stature
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study evaluated the -202 A/C insulin-like growth factor binding protein 3 (IGFBP-3) promoter polymorphism as a predictor of serum IGFBP-3 concentration and growth velocity after recombinant growth hormone (rhGH) therapy in patients with idiopathic short stature (ISS). Methods: Genotyping and serial measurement of clinical parameters were performed in 69 children with a confirmed diagnosis of ISS. Restriction fragment length polymorphism analysis was performed to determine the genotype at the -202 IGFBP-3 locus. Serum insulin-like growth factor 1 (IGF-1) and IGFBP-3 levels were measured at baseline and after 1 year of rhGH treatment, as were height standard deviation score and growth velocity. Results: The -202 A/C IGFBP-3 genotype comprised 69.6% AA, 24.6% AC, and 5.8% CC. One year of treatment did not produce a meaningful difference in IGF-1 or IGFBP-3 levels between children in the AA group and those with at least one copy of the C allele (AC/CC group). Comparing the 2 groups after one year also revealed no significant difference in growth velocity (ΔHeight: 9.061±1.612 cm/yr in the AA group, 9.421±1.864 in the AC/CC group, P=0.419). Conclusion: rhGH treatment was effective and there were no significant differences in IGF-1, IGFBP-3, or growth velocity according to genotype. Thus, -202 IGFBP-3 genotype may not be a major factor affecting individual growth responses in Korean children with ISS.
Abstract
Purpose: This study evaluated the -202 A/C insulin-like growth factor binding protein 3 (IGFBP-3) promoter polymorphism as a predictor of serum IGFBP-3 concentration and growth velocity after recombinant growth hormone (rhGH) therapy in patients with idiopathic short stature (ISS). Methods: Genotyping and serial measurement of clinical parameters were performed in 69 children with a confirmed diagnosis of ISS. Restriction fragment length polymorphism analysis was performed to determine the genotype at the -202 IGFBP-3 locus. Serum insulin-like growth factor 1 (IGF-1) and IGFBP-3 levels were measured at baseline and after 1 year of rhGH treatment, as were height standard deviation score and growth velocity. Results: The -202 A/C IGFBP-3 genotype comprised 69.6% AA, 24.6% AC, and 5.8% CC. One year of treatment did not produce a meaningful difference in IGF-1 or IGFBP-3 levels between children in the AA group and those with at least one copy of the C allele (AC/CC group). Comparing the 2 groups after one year also revealed no significant difference in growth velocity (ΔHeight: 9.061±1.612 cm/yr in the AA group, 9.421±1.864 in the AC/CC group, P=0.419). Conclusion: rhGH treatment was effective and there were no significant differences in IGF-1, IGFBP-3, or growth velocity according to genotype. Thus, -202 IGFBP-3 genotype may not be a major factor affecting individual growth responses in Korean children with ISS.
참고문헌 (34)
- Wit JM, "Idiopathic short stature : definition, epidemiology, and diagnostic evaluation", Growth Horm IGF Res, 18, pp.89~110 (2008)
- 김호성, "Efficacy of Short-Term Growth Hormone Treatment in Prepubertal Children with Idiopathic Short Stature", Yonsei Medical Journal, 55(1), pp.53~60 (2014), 연세대학교의과대학
- Ranke MB, "Towards a consensus on the definition of idiopathic short stature", Horm Res, 45(Suppl 2), pp.64~66 (1996)
- Ayyar VS, "History of growth hormone therapy", Indian J Endocrinol Metab, 15(Suppl 3), pp.S162~S165 (2011)
- Kim J, "Recombinant growth hormone therapy for prepubertal children with idiopathic short stature in Korea : a phase III randomized trial", J Endocrinol Invest, 41, pp.475~483 (2018)
- Grimberg A, "Guidelines for growth hormone and insulin-like growth factor-i treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency", Horm Res Paediatr, 86, pp.361~397 (2016)
- Deal C, "Novel promoter polymorphism in insulin-like growth factor-binding protein-3 : correlation with serum levels and interaction with known regulators", J Clin Endocrinol Metab, 86, pp.1274~1280 (2001)
- Al-Zahrani A, "IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer", Hum Mol Genet, 15, pp.1~10 (2006)
- Cheng I, "Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population", J Clin Endocrinol Metab, 92, pp.3660~3666 (2007)
- Jernström H, "Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women", Cancer Epidemiol Biomarkers Prev, 10, pp.377~384 (2001)
- Morimoto LM, "Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors", Cancer Epidemiol Biomarkers Prev, 14, pp.1394~1401 (2005)
- Ren Z, "Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women", Cancer Epidemiol Biomarkers Prev, 13, pp.1290~1295 (2004)
- Schernhammer ES, "Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk", Int J Cancer, 107, pp.60~64 (2003)
- Slattery ML, "Genetic, anthropometric, and lifestyle factors associated with IGF-1 and IGFBP-3 levels in Hispanic and non-Hispanic white women", Cancer Causes Control, 16, pp.1147~1157 (2005)
- Costalonga EF, "The -202 A allele of insulinlike growth factor binding protein-3 (IGFBP3) promoter polymorphism is associated with higher IGFBP-3 serum levels and better growth response to growth hormone treatment in patients with severe growth hormone deficiency", J Clin Endocrinol Metab, 94, pp.588~595 (2009)
- Braz AF, "The interactive effect of GHR-exon 3 and -202 A", C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome, 2012, pp.97, E671~E677
- Hyun SE, "Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3in Korean children and adolescents", Clin Biochem, 45, pp.16~21 (2012)
- Schildkraut JM, "IGF1 (CA)19repeat and IGFBP3 -202 A", C genotypes and the risk of prostate cancer in Black and White men, 2005, pp.14, 403~408
- 이민주, "Influence of The -202 A", C insulin-like growth factorbinding protein-3 promoter polymorphism on individual variation in height in Korean girl, 2017, pp.22(1), 36~42[DOI]
- Miletta MC, "Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and -202A", C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency, 2012, pp.76, 683~690
- Hendriks AE, "Common polymorphisms in the GH", IGF-1 axis contribute to growth in extremely tall subjects, 2011, pp.21, 318~324
- Wang L, "Insulin-like growth factor-binding protein-3gene-202 A", C polymorphism is correlated with advanced disease status in prostate cancer, 2003, pp.63, 4407~4411
- Xiang H, "Association between two functional polymorphisms of insulinlike growth factor binding protein 3 and colorectal cancer risk in a Chinese population", J Toxicol Environ Health A, 72, pp.706~711 (2009)
- van der Kaay DC, "Genetic and epigenetic variability in the gene for IGFBP-3 (IGFBP3): correlation with serum IGFBP-3 levels and growth in short children born small for gestational age", Growth Horm IGF Res, 19, pp.198~205 (2009)
- Ranke MB, "Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study", J Clin Endocrinol Metab, 84, pp.1174~1183 (1999)
- de Ridder MA, "Prediction of adult height in growth-hormone-treated children with growth hormone deficiency", J Clin Endocrinol Metab, 92, pp.925~931 (2007)
- Jorge AA, "Growth hormone(GH)pharmacogenetics : influence of GH receptor exon 3retention or deletion on first-year growth response and final height in patients with severe GH deficiency", J Clin Endocrinol Metab, 91, pp.1076~1080 (2006)
- Goddard AD, "Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group", N Engl J Med, 333, pp.1093~1098 (1995)
- Meyer S, "Short stature and decreased insulin-like growth factor I (IGF-I)", growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor, 2007, pp.17, 307~314
- Ferry RJ Jr, "Insulin-like growth factor binding proteins : new proteins, new functions", Horm Res, 51, pp.53~67 (1999)
- Hopwood NJ, "Growth response of children with nongrowth-hormone deficiency and marked short stature during three years of growth hormone therapy", J Pediatr, 123, pp.215~222 (1993)
- Wit JM, "Idiopathic short stature : management and growth hormone treatment", Growth Horm IGF Res, 18, pp.111~135 (2008)
- Wudy SA, "Children with idiopathic short stature are poor eaters and have decreased body mass index", Pediatrics, 116, pp.e52~e57 (2005)
- Roman R, "The IGF-I response to growth hormone is related to body mass index in short children with normal weight", Horm Res, 72, pp.10~14 (2009)